4.8 Review

Pluripotent stem cells in neuropsychiatric disorders

Journal

MOLECULAR PSYCHIATRY
Volume 22, Issue 9, Pages 1241-1249

Publisher

SPRINGERNATURE
DOI: 10.1038/mp.2017.40

Keywords

-

Funding

  1. Swiss National Science Foundation Mobility fellowship [PA00PA3-142203/1, P300P3-154667]
  2. Cornell University Medical College
  3. New York County Society of Psychiatry
  4. Thermo-Fischer Scientific
  5. Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health [T32GM007739]
  6. National Institutes of Health [NINDS: R01NS072381, R21 NS084334, NCI: P30 CA008748]
  7. Tri-institutional stem cell initiative (Starr Foundation)
  8. NYSTEM [C026446, C026447]
  9. Swiss National Science Foundation (SNF) [P300P3_154667] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Neuropsychiatric disorders place an enormous medical burden on patients across all social and economic ranks. The current understanding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to a lack of targeted therapies. Human-induced pluripotent stem cell (iPSC) technology offers a novel platform for modeling the genetic contribution to mental disorders and yields access to patient-specific cells for drug discovery and personalized medicine. Here, we review recent progress in using iPSC technology to model and potentially treat neuropsychiatric disorders by focusing on the most prevalent conditions in psychiatry, including depression, anxiety disorders, bipolar disorder and schizophrenia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available